GENIS HF

Their core work

GENIS HF is an Icelandic biotech SME based in Siglufjörður that extracts and develops bioactive compounds from North Atlantic marine sources for health and medical applications. Their core product line centers on chitin oligosaccharides — natural polysaccharides derived from marine organisms — which they are developing as therapeutic agents targeting inflammatory conditions such as arthritis and as adjuvant nutraceuticals supporting cancer treatment. They followed the classic SME Instrument pathway: a Phase 1 feasibility study in 2017 validated the concept, followed by a Phase 2 development project (€1.5M) from 2018 to 2020 focused on breast, lung, and pancreatic cancer indications. Their work sits at the intersection of marine biotechnology, nutraceutical science, and oncology support.

What they specialise in

How they've shifted over time

GENIS HF's trajectory across their two H2020 projects shows a deliberate strategic narrowing from a broad anti-inflammatory concept toward oncology support — a higher-value, higher-impact market. The 2017 Phase 1 project explored chitin oligosaccharides for arthritis, establishing proof of concept for the marine compound platform. By 2018 the company pivoted that same core material toward adjuvant cancer treatment, suggesting they identified oncology as a stronger commercial and scientific opportunity. The pattern is one of platform deepening rather than diversification: one marine-derived compound family, progressively more serious disease indications.

GENIS HF is moving up the therapeutic value chain — from inflammatory conditions toward oncology support — using the same marine bioactive platform, which suggests future partnerships in clinical nutraceuticals or drug-adjacent health products.

How they like to work

GENIS HF operates exclusively as a solo coordinator under the SME Instrument, which is designed for single-company innovation projects — so the absence of consortium partners is structural, not a choice. This means they are a self-contained innovation unit that drives their own R&D agenda rather than a consortium builder. Anyone seeking to collaborate with them would likely engage as a technology licensee, clinical partner, or distributor, rather than as a co-applicant in a joint project.

GENIS HF has no recorded consortium partners in H2020 data, which is expected for SME Instrument grants where solo applications are the norm. Their effective network — subcontractors, clinical validators, research collaborators — is not visible in CORDIS but almost certainly exists outside formal consortium structures.

What sets them apart

GENIS HF is one of very few Icelandic SMEs working on therapeutic applications of marine-derived polysaccharides from North Atlantic sources, giving them a rare combination of geographic proximity to raw material and biotech development capability. Their location in Siglufjörður — a fishing town with direct access to marine biomass — is not incidental: it likely underpins both supply chain and local knowledge advantages that larger, urban biotech firms cannot easily replicate. For a consortium needing a credible North Atlantic marine bioactive supplier with clinical ambitions, they are a distinctive and hard-to-substitute partner.

Highlights from their portfolio

• Simecos (Phase 2)
  With €1.526M in EC funding, this is the company's flagship project and one of the larger SME Instrument Phase 2 grants in the nutraceutical space, targeting three high-mortality cancer types with a single marine-derived compound.
• Simecos (Phase 1)
  The €50k feasibility study that validated the chitin oligosaccharide platform and directly enabled the Phase 2 grant — a textbook SME Instrument progression rarely achieved by small Icelandic companies.